<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Members of the <z:chebi fb="0" ids="25696">organic anion</z:chebi> transporter family (OATP) mediate the transmembrane uptake of clinical important drugs and hormones thereby affecting drug disposition and tissue penetration </plain></SENT>
<SENT sid="1" pm="."><plain>Particularly OATP subfamily 1 is known to mediate the cellular uptake of anticancer drugs (e.g., <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, derivatives of <z:chebi fb="6" ids="45863">taxol</z:chebi> and <z:chebi fb="0" ids="27656">camptothecin</z:chebi>, flavopiridol, and <z:chebi fb="0" ids="45783">imatinib</z:chebi>) </plain></SENT>
<SENT sid="2" pm="."><plain>Tissue-specific expression was shown for OATP1B1/OATP1B3 in liver, OATP4C1 in kidney, and OATP6A1 in testis, while other OATPs, for example, OATP4A1, are expressed in multiple cells and organs </plain></SENT>
<SENT sid="3" pm="."><plain>Many different <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> entities show an altered expression of OATPs </plain></SENT>
<SENT sid="4" pm="."><plain>OATP1B1/OATP1B3 are downregulated in <z:e sem="disease" ids="C0023903" disease_type="Neoplastic Process" abbrv="">liver tumors</z:e>, but highly expressed in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in the gastrointestinal tract, breast, prostate, and lung </plain></SENT>
<SENT sid="5" pm="."><plain>Similarly, testis-specific OATP6A1 is expressed in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in the lung, brain, and bladder </plain></SENT>
<SENT sid="6" pm="."><plain>Due to their presence in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> tissues and their limited expression in <z:mpath ids='MPATH_458'>normal</z:mpath> tissues, OATP1B1, OATP1B3, and OATP6A1 could be a target for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> immunotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>Otherwise, high levels of ubiquitous expressed OATP4A1 are found in <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> and their <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, this OATP might serve as biomarkers for these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Expression of OATP is regulated by nuclear receptors, inflammatory cytokines, tissue factors, and also posttranslational modifications of the proteins </plain></SENT>
<SENT sid="10" pm="."><plain>Through these processes, the distribution of the transporter in the tissue will be altered, and a shift from the plasma membrane to cytoplasmic compartments is possible </plain></SENT>
<SENT sid="11" pm="."><plain>It will modify OATP uptake properties and, subsequently, change intracellular concentrations of drugs, hormones, and various other OATP substrates </plain></SENT>
<SENT sid="12" pm="."><plain>Therefore, screening <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> for OATP expression before therapy should lead to an OATP-targeted therapy with higher efficacy and decreased side effects </plain></SENT>
</text></document>